Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Ma A. Gomez-Espana et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry
Minsoo Son et al.
CLINICAL CANCER RESEARCH (2021)
Extracellular heat shock proteins and cancer: New perspectives
Zarema Albakova et al.
TRANSLATIONAL ONCOLOGY (2021)
Down-regulation of metabolic pathways could offset the poor prognosis conferred by co-existent diabetes mellitus in pancreatic (head) adenocarcinoma
Nilesh Gardi et al.
ANZ JOURNAL OF SURGERY (2021)
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Liwei Cao et al.
CELL (2021)
Immunotherapy in Pancreatic Adenocarcinoma: Beyond Copy/Paste
Robert Hester et al.
CLINICAL CANCER RESEARCH (2021)
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Henry C-H Law et al.
CLINICAL CANCER RESEARCH (2020)
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
Gabriela Reyes-Castellanos et al.
BIOMEDICINES (2020)
Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival
Matilda Holm et al.
TUMOR BIOLOGY (2020)
Complement System: Promoter or Suppressor of Cancer Progression?
Margot Revel et al.
ANTIBODIES (2020)
Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases
Ashton A. Connor et al.
CANCER CELL (2019)
CD90 highly expressed population harbors a sternness signature and creates an immunosuppressive niche in pancreatic cancer
Juanjuan Shi et al.
CANCER LETTERS (2019)
Role of the complement system in the tumor microenvironment
Ronghua Zhang et al.
CANCER CELL INTERNATIONAL (2019)
Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages
Haoran Zha et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
R. Tuli et al.
EBIOMEDICINE (2019)
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2018)
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
Elisabetta Marangoni et al.
CLINICAL CANCER RESEARCH (2018)
Label-Free Quantitative Proteomics Unravels Carboxypeptidases as the Novel Biomarker in Pancreatic Ductal Adenocarcinoma
Yang Song et al.
TRANSLATIONAL ONCOLOGY (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
Andrew H. Ko et al.
ONCOLOGIST (2017)
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer
Jair Machado Espindola-Netto et al.
ONCOTARGET (2017)
Functional proteomics outlines the complexity of breast cancer molecular subtypes
Angelo Gamez-Pozo et al.
SCIENTIFIC REPORTS (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
Mitochondrial mutations and metabolic adaptation in pancreatic cancer
Rae-Anne Hardie et al.
CANCER & METABOLISM (2017)
The role of pharmacogenetics in capecitabine efficacy and toxicity
S. W. Lam et al.
CANCER TREATMENT REVIEWS (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
The Perseus computational platform for comprehensive analysis of (prote)omics data
Stefka Tyanova et al.
NATURE METHODS (2016)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications
Angelo Gamez-Pozo et al.
CANCER RESEARCH (2015)
Fitting Linear Mixed-Effects Models Using lme4
Douglas Bates et al.
JOURNAL OF STATISTICAL SOFTWARE (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
High-Dimensional Graphical Model Search with thegRapHDRPackage
Gabriel C. G. Abreu et al.
Journal of Statistical Software (2015)
Ran GTPase protein promotes metastasis and invasion in pancreatic cancer by deregulating the expression of AR and CXCR4
Lin Deng et al.
CANCER BIOLOGY & THERAPY (2014)
A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells
Jianliang Zhang et al.
CELL CYCLE (2014)
Overexpression of CD90 (Thy-1) in Pancreatic Adenocarcinoma Present in the Tumor Microenvironment
Jianhui Zhu et al.
PLOS ONE (2014)
Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: Up-regulation of Complement C3 and alpha-2-HS-glycoprotein
Jiong Chen et al.
PANCREATOLOGY (2013)
Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer
Jiong Chen et al.
ONCOLOGY LETTERS (2013)
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Claus Schaefer et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases
Kalnisha Naidoo et al.
JOURNAL OF PATHOLOGY (2012)
BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Niranjan Awasthi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1-STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival
Angelo A. Cardoso et al.
PLOS ONE (2012)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
Christina L. Costantino et al.
CANCER RESEARCH (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips
Juri Rappsilber et al.
NATURE PROTOCOLS (2007)
DrugBank: a comprehensive resource for in silico drug discovery and exploration
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2006)
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity
SJ Kridel et al.
CANCER RESEARCH (2004)
Mass spectrometry-based proteomics
R Aebersold et al.
NATURE (2003)
TM4: A free, open-source system for microarray data management and analysis
AI Saeed et al.
BIOTECHNIQUES (2003)
Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: Relationship with microsatellite instability
D Hardisson et al.
MODERN PATHOLOGY (2003)
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
SG Eckhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
